These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7656098)

  • 21. [Maintenance therapy of mild form of GERD by H2 receptor antagonists].
    Kurosawa S
    Nihon Rinsho; 2000 Sep; 58(9):1859-64. PubMed ID: 11004816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
    McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
    Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
    Barkun AN; Adam V; Martel M; Bardou M
    Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Proton pump inhibitor H2 receptor antagonist].
    Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
    Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Achieving pH control in the critically ill patient: the role of continuous infusion of H2-receptor antagonists.
    Moore JG
    DICP; 1990 Nov; 24(11 Suppl):S28-30. PubMed ID: 1980180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gastric acid secretion inhibitors: H2 receptor antagonists (H2RA), proton pump inhibitors (PPI) or acid pump antagonists (APA)].
    Mazure PA
    Acta Gastroenterol Latinoam; 1996; 26(4):263-5. PubMed ID: 9335935
    [No Abstract]   [Full Text] [Related]  

  • 27. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence.
    Manlucu J; Tonelli M; Ray JG; Papaioannou A; Youssef G; Thiessen-Philbrook HR; Holbrook A; Garg AX
    Nephrol Dial Transplant; 2005 Nov; 20(11):2376-84. PubMed ID: 16091377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of H2 receptor antagonists for prevention of upper gastrointestinal bleeding during dual-antiplatelet therapy.
    Yasu T; Sato N; Kurokawa Y; Saito S; Shoji M
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):854-60. PubMed ID: 24040853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
    Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
    Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
    Rackoff A; Agrawal A; Hila A; Mainie I; Tutuian R; Castell DO
    Dis Esophagus; 2005; 18(6):370-3. PubMed ID: 16336606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock.
    Barletta JF
    Ann Pharmacother; 2014 Oct; 48(10):1276-81. PubMed ID: 24982312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib.
    Lam LH; Capparelli EV; Kurzrock R
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):427-32. PubMed ID: 27372908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic effect of low-dose omeprazole vs. standard-dose ranitidine in mild to moderate reflux esophagitis].
    Kim JW; Kim HS; Lee DK; Suk KT; Kim JM; Baik SK; Kwon SO; Cho MY
    Korean J Gastroenterol; 2004 Mar; 43(3):153-9. PubMed ID: 15034285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical treatments in the short term management of reflux oesophagitis.
    Khan M; Santana J; Donnellan C; Preston C; Moayyedi P
    Cochrane Database Syst Rev; 2007 Apr; (2):CD003244. PubMed ID: 17443524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis.
    Moayyedi P; Santana J; Khan M; Preston C; Donnellan C
    Cochrane Database Syst Rev; 2011 Feb; (2):CD003244. PubMed ID: 21328259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parenteral nutrient admixtures as drug vehicles: theory and practice in the critical care setting.
    Driscoll DF; Baptista RJ; Mitrano FP; Mascioli EA; Blackburn GL; Bistrian BR
    DICP; 1991 Mar; 25(3):276-83. PubMed ID: 1674183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent versus mild acid suppression in peptic ulcer disease.
    Howden CW
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():45-6. PubMed ID: 1349552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment and prevention of histamine-2 receptor antagonist for elderly gastric ulcer].
    Kamada T; Sato Y; Shiotani A; Haruma K
    Nihon Rinsho; 2010 Nov; 68(11):2064-70. PubMed ID: 21061534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of intravenous H2-receptor antagonists in a tertiary care hospital.
    Dettmer RM; Riley TH; Byfield F; Green PH
    Am J Gastroenterol; 1999 Dec; 94(12):3473-7. PubMed ID: 10606306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influencing parenteral histamine2-receptor antagonist use.
    Sesin GP; Provost PS; O'Keefe EM
    DICP; 1989 Oct; 23(10):812. PubMed ID: 2573203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.